Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?

被引：16

作者：

Han, Leo ^{[1
]}

Jensen, Jeffrey T. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA

来源：

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA | 2015年 / 42卷 / 04期

关键词：

Progestin; Progestogen; Venous thromboembolism; Oral contraceptive; Drospirenone; 3RD-GENERATION ORAL-CONTRACEPTIVES; V-LEIDEN MUTATION; MYOCARDIAL-INFARCTION; TRANSDERMAL PATCH; ACTIVE SURVEILLANCE; BINDING GLOBULIN; THROMBOEMBOLISM; WOMEN; DROSPIRENONE; SAFETY;

D O I：

10.1016/j.ogc.2015.07.007

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Combined hormonal contraceptives (CHCs) use a combination of estrogen and progestogen to provide contraception. The most important risk of using CHCs is venous thromboembolism (VTE). It is unclear whether the type of progestogen used in a method augments that risk. Although the evidence supporting an increase in thrombosis risk is not conclusive, neither is the evidence supporting the benefit of newer progestogens in terms of tolerability or continuation. The benefits of CHCs outweigh the risks and the absolute risk of VTE remains small. A balanced discussion of potential risks and benefits of particular CHC formulations is warranted during contraception counseling.

引用

页码：683 / +

页数：17

共 64 条

[41] Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? A discussion based on recent recommendations from the European agency for evaluation of medicinal products regarding third generation oral contraceptive pills [J].

Odlind, V ;

Milsom, I ;

Persson, I ;

Victor, A .

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2002, 81 (06) :482-490

[42] Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008 [J].

Okoroh, Ekwutosi M. ;

Hooper, W. Craig ;

Atrash, Hani K. ;

Yusuf, Hussain R. ;

Boulet, Sheree L. .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (05) :377.e1-377.e8

[43] Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database [J].

Parkin, Lianne ;

Sharples, Katrina ;

Hernandez, Rohini K. ;

Jick, Susan S. .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 342

[44]

POULTER NR, 1995, LANCET, V346, P1575

[45]

Poulter NR, 1996, LANCET, V348, P498

[46] Oral Contraceptives and Venous Thromboembolism Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009 [J].

Reid, Robert L. ;

Westhoff, Carolyn ;

Mansour, Diana ;

de Vries, Corrine ;

Verhaeghe, Johan ;

Boschitsch, Ewald ;

Gompel, Anne ;

Birkhaeuser, Martin ;

Krepelka, Petr ;

Dulicek, Petr ;

Iversen, Ole-Erik ;

Khamoshina, Marina ;

Dezman, Lucija Vrabic ;

Fruzzetti, Franca ;

Szarewski, Anne ;

Wilken-Jensen, Charlotte ;

Seidman, Daniel ;

Kaaja, Risto ;

Shapiro, Samuel .

JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2010, 36 (03) :117-122

[47]

Schulz KF., 2006, The Lancet Handbook of Essential Concepts in Clinical Research

[48] Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies [J].

Shapiro, Samuel ;

Dinger, Juergen .

JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2010, 36 (01) :33-38

[49]

Speroff L., 2010, A clinical guide for contraception, V5th

[50]

Spitzer WO, 1996, BRIT MED J, V312, P83

← 1 2 3 4 5 6 7 →